Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for ALK-positive non-small-cell lung cancer, drawn from the whole corpus: 16 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Whether any sequence of inhibitors cures metastatic ALK-positive disease or only holds it is unknown.
Nothing recorded yet.
Background: Oligoprogression. Also on OnCo: Atlas of advanced disease · How cancer spreads: the metastasis stages.
Lorlatinib's cognitive, mood and metabolic effects are managed by dose reduction without trials of the optimal dose.
Resistance after lorlatinib is compound mutations and bypass pathways with no approved option.
Nothing recorded yet.
Background: Drug resistance (primary and acquired), Oligoprogression, On-target resistance mutations (gatekeeper, solvent-front, compound). Also on OnCo: Resistance atlas · Lines of therapy.
The right duration of adjuvant alectinib is untested; recurrences after stopping are being watched.
Nothing recorded yet.
Background: Neoadjuvant / adjuvant / perioperative. Also on OnCo: Treatment journeys · Survivorship planner.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 24 changes by month →When this page itself was last checked or edited.
ORR 31% in heavily pretreated ALK+ NSCLC; NDA under priority review.
Adjuvant ALK+ NSCLC after resection (stage IB ≥4 cm to IIIA)
A milestone in how this cancer is treated.
ALK-positive non-small-cell lung cancer after crizotinib; first line from 2024
DFS HR 0.